The dumping of a controversial Trump administration rule limiting what 340B health centers can charge patients for insulin and EpiPen-type devices took a big step closer to being finalized last week.
Late last week Thursday, the U.S. Health Resources
…
Nine friend-of-the-court briefs have been filed in the nation’s highest court urging rejection of an appeals court’s decision last year that upheld a huge cut in 340B hospitals’ Medicare reimbursement for physician administered drugs.
Thirty-seven state and regional hospital associations
…
Napo Pharmaceuticals yesterday posted a public notice to 340B covered entities about how to obtain 340B pricing on Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs.
Napo said in the notice on the U.S. Health
…
340B covered entities are breathing easier today upon learning that U.S. House Democrats excluded much-feared Medicaid managed care “spread pricing” language from forthcoming drug pricing legislation.
The House Energy & Commerce Committee late yesterday released the text of the 16
…
U.S. Health and Human Services Secretary Xavier Becerra yesterday reiterated HHS’ “strong support for the 340B Drug Pricing Program” in a 29-page plan to lower drug prices.
Becerra’s Sept. 9 report to White House domestic and economic policy counselors
…
With the deadline for hospitals to recertify their eligibility for 340B drug discounts arriving on Monday, it appears most facilities will remain qualified—at least for now.
Industry observers say the COVID-19 pandemic’s impact on hospitals’ eligibility for 340B could become
…
The only clear path to resolve the impasse over the legality of 340B contract pharmacy arrangements is for Congress to clarify the 340B law, 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell.
Urging
…
Federal health officials have added New Jersey and New York to the list of states granted 340B enrollment flexibility due to Hurricane Ida.
The U.S. Health Resources and Services Administration (HRSA) posted the notice about the East Coast states’ addition
…
340B covered entities are ramping up their lobbying on Capitol Hill as Congress works toward possible enactment soon of major drug pricing reforms.
Entities are telling key members of Congress and their staffs that while they support federal action to
…
Community health centers on Tuesday split their 340B dispute resolution petition against drug manufacturers Eli Lilly, Sanofi, and AstraZeneca into two—one against Lilly alone, the other against Sanofi and AstraZeneca together—to let federal officials commence proceedings against Sanofi and AstraZeneca.
…*Sign up for news summaries and alerts from 340B Report